Influence of irbesartan on blood pressure and proteinuria in patients with chronic glomerulonephritis

Abstract

Abstract: AIM: To investigate the influence of irbesartan on blood pressure and proteinuria in patients with chronic glomerulonephritis. METHODS: 27 patients with chronic glomerulonephritis were treated with irbesartan for 8 wk.Blood pressure, proteinuria, renal function, serum K⁺, liver function, and serum lipid were detected before and after 8 wk. RESULTS: The levels of blood pressure and 24 h proteinuria were decreased significantly (P <0.01) 8 wk after the administration, but the renal function, serum K⁺, liver function and serum lipid were unchanged. CONCLUSION: Irbesartan shows a stable anti-hypertensive effect and can reduce proteinuria in patients with chronic glomerulonephritis.

Key words: pharmacoidynamics, irbesartan, chronic glomerulonephritis, hypertension, proteinuria

CLC Number:

LIU Hong, YU Ji-Rong, LIU Bi-Cheng, WANG Yan-Li, YIN Lian-Fang, ZHANG Xiao-Liang. Influence of irbesartan on blood pressure and proteinuria in patients with chronic glomerulonephritis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 95-97.

References

[1] Lewis EJ, Hunsicker LG, Clapke WR, et al.Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J].N Engl J Med, 2001;345:851-60
[2] Parving HH, Lehnert H, Brochner-mortensen J, et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J].N Engl JMed, 2001;345:861-9
[3] Mezzano SA, Ruiz-Ortega M, Egido J.Angiotensin Ⅱ and renal fibrosis[J].Hyperteion, 2001;38:635-8
[4] Wolf G, Haberstroh U, Neilson EG.Angiotensin Ⅱ stimulates the proliferation and biosynthesis of type ? collagen in cultured murine mesangialcells[J].Am J Pathol, 1992;140:95-107
[5] Zatz R, Dunn BR, Meyer TW, et al.Prevention of diabet glomerulopathy by pharmacological amelioration of glomerular capillary hypertention[J].J Clin Invest, 1986;77:1925-30
[6] Abbate M, Zoja C, Corna D, et al.In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation[J].J Am Soc Nephrol, 1998;9:1213-24
[7] O' donnell MP, Crary GS, Oda H, et al.Irbesartan lowers blood pressor and ameliorates renal injury in experimental noninsulin-dependent diabetes mellitus[J].Kindey Int, 1997;52(63 Supple 1):S218-S20
[8] Lewis EJ, Hunsicker LG, Bain RP, et al.The effect of angiotensin-coverting enzyme inhibition on diabetic nephropathy[J].N Engl J Med, 1993;329:1456-62
[9] Burnier M, Brunner HR.Angiotensin receptor antagonists[J].Lancet, 2000, 355:637-47
[10] 刘必成, 罗冬冬, 孙子林, 等.结缔组织生长因子在糖尿病大鼠肾脏中的表达及意义探讨[J].东南大学学报(医学版), 2002;1:36-9
[11] 罗冬冬, 刘必成, 张东升, 等.Irbesartan 对糖尿病大鼠毛细血管基底膜增厚的影响[J].东南大学学报(医学版),2002;1:89-92
[12] 罗冬冬, 刘必成, 王兆明, 等.伊贝沙坦对糖尿病大鼠结缔组织生长因子表达的影响[J].中国药科大学学报,2002;38:327-30

[1]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[2]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[3]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[4]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[5]	GAO Jiarong, SHI Miaomiao, CHEN Hao, JIANG Hui, QIN Xiujuan. Effect of Qiteng Xiaozhuo granule mediating miR-339-5p on inflammatory indexes in rats with chronic glomerulonephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 457-465.
[6]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[7]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[8]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[9]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[10]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[11]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[12]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[13]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
[14]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[15]	YE Peng, TAN Xing, LENG Yueqi, WANG Yangkai, WANG Weizhong. Current opinions and developments of non-pharmacological treatments of hypertension based on sympathetic nervous system [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1335-1343.